GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Erasca Inc.
Erasca is a biotech company focused on developing drugs to treat cancers caused by mutations in the RAS signaling pathway. Its stock price represents a venture bet on a breakthrough in one of the most challenging areas of oncology.
Share prices of companies in the market segment - Cancer cure
Erasca is a biotech company whose mission is to eradicate cancer. It focuses on developing targeted therapies that target key oncogenic pathways. We classify it in the Cancer Treatment segment. The chart below reflects the overall dynamics of this high-risk but promising sector.
Broad Market Index - GURU.Markets
Erasca is an oncology company developing targeted therapies for cancers caused by mutations in the RAS/MAPK signaling pathway. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Erasca shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ERAS - Daily change in the company's share price Erasca Inc.
Shares of Erasca, an oncology company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to news about clinical trials. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Cancer cure
Erasca, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ERAS's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Erasca is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Erasca shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Erasca Inc.
Erasca, Inc.'s year-over-year performance is a classic story for a clinical-stage biotech company. Its 12-month market cap depends entirely on progress in cancer drug development. Any data from the lab or early trials could radically change investor valuations, as these are potential blockbusters.
Annual dynamics of market capitalization of the market segment - Cancer cure
Erasca, Inc. is a clinical-stage biotech focused on developing drugs to treat cancers caused by RAS mutations. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Erasca is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Erasca Inc.
The value of Erasca, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its oncology drug clinical trials, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Erasca is a biotech company focused on developing targeted therapies for cancers caused by mutations in the RAS family of genes, which have long been considered untreatable. The chart below shows the overall dynamics in the oncology sector, reflecting the race to develop drugs against the most challenging targets.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Early-stage biotech stocks are a venture capital bet on science. The chart below shows investors' overall risk appetite. Is Erasca, Inc. moving at an extreme amplitude, amplifying market movements, as is typical for such stories?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Erasca Inc.
Erasca, an oncology company targeting key cancer cell signaling pathways, is extremely sensitive to scientific news. Its weekly stock price reflects data from preclinical and clinical trials.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Erasca operates in the highly competitive oncology sector, where investor sentiment drives the overall trend. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether ERAS is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Erasca, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how ERAS shares can rise or fall on news releases while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
ERAS - Market capitalization of the company Erasca Inc.
Erasca's chart reflects an ambitious mission to eradicate cancer. This biotech's market cap reflects investors' faith in its pipeline of drugs targeting key oncogenic pathways. Its volatile dynamics are a classic biotech story, where every research result can dramatically change the company's valuation.
ERAS - Share of the company's market capitalization Erasca Inc. within the market segment - Cancer cure
Erasca is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers caused by mutations in the RAS/MAPK signaling pathway. Its market capitalization reflects the potential of its developments. The chart below shows the volatility associated with the progress of clinical trials.
Market capitalization of the market segment - Cancer cure
Erasca, Inc. is a biotech company whose mission is to "eradicate" cancer by developing targeted drugs against key oncogenes. The chart below shows the market capitalization of the entire oncology sector. This represents an assessment of this ambitious goal and the search for fundamental solutions in the fight against cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Erasca is a biotech company focused on developing targeted therapies for cancers caused by mutations in the RAS signaling pathway. The company's market capitalization is a bet on its ability to crack one of the most challenging targets in oncology. Its market share represents the hope of developing drugs against the most common and deadly cancers.
Book value capitalization of the company, segment and market as a whole
ERAS - Book value capitalization of the company Erasca Inc.
Erasca is built on a foundation of cancer capital. The biotech's book value reflects its intellectual property in its pipeline of targeted therapies and, most importantly, its vast cash reserves to support numerous clinical trials. The chart below shows how the company is leveraging its financial foundation in the war on cancer.
ERAS - Share of the company's book capitalization Erasca Inc. within the market segment - Cancer cure
Erasca, Inc., an oncology company, is focused on R&D. Its tangible assets are research laboratories. The S_BCap_Seg chart shows its small stake in physical infrastructure, which is typical for a biotech company in clinical development.
Market segment balance sheet capitalization - Cancer cure
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Erasca, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Erasca is a biotech company focused on "erasing" cancer by targeting key oncogenes. The company's assets include a portfolio of promising molecules and a scientific platform for their development. The chart below illustrates the financial weight behind this ambitious mission in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Erasca Inc.
Erasca's balance sheet is cash in research accounts. The market isn't assessing this, but rather the company's ambitious goal of "erasing cancer" with a new approach to targeted therapy. The chart will show how much more valuable this "great goal" and hope for a breakthrough can be than all its tangible assets.
Market to book capitalization ratio in a market segment - Cancer cure
Erasca, Inc. is a biotech company focused on developing targeted therapies for cancer treatment. Its value is entirely dependent on the success of its drugs in clinical trials. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current tangible assets.
Market to book capitalization ratio for the market as a whole
Erasca is a biotech company focused on developing drugs to treat cancer caused by specific mutations. Its value depends almost entirely on the success of its drugs in clinical trials. This chart is a classic example of biotech startup valuation, with investors betting on a future breakthrough in targeted oncology.
Debts of the company, segment and market as a whole
ERAS - Company debts Erasca Inc.
Erasca, a biotech focused on fighting cancer, uses raised capital to fund its broad portfolio of preclinical and clinical programs. This chart shows how the company is making multiple bets on different treatment approaches, requiring significant and ongoing investment in R&D.
Market segment debts - Cancer cure
Erasca is a biotech company focused on developing drugs to treat cancers caused by mutations in the RAS signaling pathway. This is one of the most complex areas in oncology. This chart shows how the company's debt burden reflects its need to fund long-term and expensive research to address this fundamental scientific challenge.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Erasca Inc.
Erasca is a biotech company focused on developing drugs for cancers caused by mutations in the RAS gene. This is one of the most challenging targets in oncology. This chart shows how the company is funding its ambitious and high-risk research, which, if successful, could change the paradigm of cancer treatment.
Market segment debt to market segment book capitalization - Cancer cure
Erasca, a clinical-stage biotech focused on developing targeted therapies for cancers caused by mutations in the RAS signaling pathway, is a company focused on developing targeted therapies for cancers caused by mutations in the RAS signaling pathway. This chart compares its debt load to the total market capitalization of the oncology sector. It shows how the company is funding its ambitious research.
Debt to book value of all companies in the market
Erasca, Inc. is a biotech company focused on developing drugs for cancers caused by mutations in the RAS signaling pathway. This is one of the most challenging targets in oncology. This chart of total debt in the market shows the overall availability of capital for these ambitious and risky research projects, which have the potential to revolutionize cancer treatment.
P/E of the company, segment and market as a whole
P/E - Erasca Inc.
This chart from Erasca, Inc., a clinical-stage oncology company, shows the valuation of its mission to develop drugs against cancers caused by mutations in the RAS/MAPK signaling pathway. It is not profitable. The metric reflects investor hopes that its scientific approach will lead to breakthroughs in the treatment of some of the most common and difficult-to-treat tumors.
P/E of the market segment - Cancer cure
Erasca, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancers caused by mutations in the RAS/MAPK signaling pathway. This chart illustrates the average valuation in the oncology development sector, where investors are betting on companies attacking some of the most complex and common oncogenic drivers.
P/E of the market as a whole
Erasca is a biotech company focused on developing targeted therapies for cancers caused by mutations in the RAS signaling pathway. This chart shows the overall risk appetite in the biotech sector. Comparing it shows how much Erasca's valuation is driven by confidence in its ability to solve one of the most challenging problems in oncology, rather than by overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Erasca Inc.
This chart for Erasca, Inc., a biotech company focused on cancer treatment, shows market expectations for its extensive clinical pipeline. It reflects investor confidence that one or more of its drug candidates will be successful and generate significant profits.
%20P%2FE%20Erasca%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Erasca-Inc.&v=1772568392392 "Chart of the company's future (projected) P/E Erasca Inc.")
Future (projected) P/E of the market segment - Cancer cure
Erasca, Inc. is a biotech company focused on finding cures for cancers caused by mutations in the RAS signaling pathway. This chart shows average expectations for the biotech sector. ERAS's position may indicate the extent to which investors believe it can solve one of the most challenging problems in oncology and create breakthrough drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772568392485 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Erasca, Inc. is an oncology company focused on fighting cancer. Its value is entirely dependent on progress in clinical trials. Overall investor sentiment, visible on this chart, sets the stock's context, but for Erasca, lab news is the primary driver.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772568392647 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Erasca Inc.
Erasca, Inc. is a biotechnology company focused on developing cancer drugs by targeting key RAS/MAPK signaling pathways. This chart reflects fundamental research in oncology. It shows investments in a broad pipeline of drug candidates, with future revenue dependent on their success in clinical trials.
Profit of companies in the market segment - Cancer cure
Erasca, Inc. is a biotechnology company focused on developing drugs for cancers caused by mutations in the RAS family of genes. Profitability in this cutting-edge oncology segment, as this chart shows, is a bet on scientific breakthroughs. For ERAS, success in developing a cure for these difficult-to-treat tumors would be revolutionary and generate enormous value.
Overall market profit
Erasca, Inc., a biopharmaceutical company focused on fighting cancer caused by specific mutations, operates at the forefront of science. Its value is determined by progress in clinical trials. The overall market situation, shown in this chart, is critical to raising the capital needed to fund its long-term and risky research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Erasca Inc.
Erasca is a biotech company focused on developing cancer drugs by targeting key signaling pathways. This chart reflects analyst forecasts, which are betting on the success of its extensive pipeline in clinical trials.
%20profit%20of%20the%20company%20Erasca%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Erasca-Inc.&v=1772568392985 "Graph of future (projected) profit of the company Erasca Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Erasca, Inc. is a biotech company whose mission is to "erase" cancer. It is focused on developing targeted therapies that target key oncogenic drivers. Its value lies in its scientific potential. This chart shows the revenue forecast for the cancer treatment sector, reflecting the overall investor confidence in breakthrough approaches and personalized oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772568393065 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Erasca, Inc. is a biotechnology company focused on developing cancer treatments. Its valuation depends on the success of clinical trials. The overall profit forecast is important for assessing the investment climate. During market downturns, investors tend to be risk-averse, making raising capital more challenging for early-stage companies like Erasca.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772568393127 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Erasca Inc.
Erasca, Inc. is a biotech company focused on developing oncology drugs that target key signaling pathways in cancer cells. Being in clinical trials, its revenue is minimal. The chart reflects investors' heavy betting on the scientific potential of its developments and future blockbusters, rather than on current cash flows.
P/S market segment - Cancer cure
Erasca, Inc. is a biotech company whose mission is to "erase" cancer. It develops targeted drugs against key oncogenic mutations. The chart shows the average revenue estimate for the biotech company. It allows one to assess how highly investors value its ambitious mission and scientific portfolio compared to the oncology sector average.
P/S of the market as a whole
Erasca, Inc. is a biotech company focused on developing drugs against cancers caused by mutations in the RAS signaling pathway, long considered an elusive target. This is the holy grail of oncology. The graph of average market revenue estimates shows that investors are investing in the hope of a fundamental breakthrough in cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Erasca Inc.
Erasca, Inc. is a biotech company focused on developing targeted therapies for cancer caused by mutations in the RAS signaling pathway. The chart reflects investor expectations for a breakthrough in this complex field. The company's value is based on projected future revenues from its innovative drugs, should they prove successful.
%20P%2FS%20Erasca%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Erasca-Inc.&v=1772568393420 "The graph of the company's future (projected) P/S Erasca Inc.")
Future (projected) P/S of the market segment - Cancer cure
Erasca, Inc. is a biotechnology company focused on developing drugs to treat cancers caused by mutations in the RAS/MAPK signaling pathway. This chart shows the average future sales estimates for oncology companies. It helps understand how highly the market values Erasca's scientific approach to one of the most challenging targets in oncology and its pipeline of candidates.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772568393445 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Erasca, Inc. is a biotech company focused on fighting cancer by targeting key signaling pathways. Its value lies in the potential of its scientific developments. This revenue expectation schedule is irrelevant to the company. Investors are focused entirely on clinical trial data, which will determine its future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772568393455 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Erasca Inc.
Erasca is a biotech company focused on developing targeted therapies for cancer. Being in the clinical stage, it likely has no sales revenue. Revenue, if reflected in this chart, likely comes from partnerships that help fund its extensive research pipeline.
Sales of companies in the market segment - Cancer cure
Erasca, Inc. is a biotechnology company whose mission is to find a cure for cancer. The company focuses on developing targeted therapies that target key oncogenic drivers that drive tumor growth. This chart shows the sector's total revenue, reflecting the enormous effort and investment devoted to fighting cancer.
Overall market sales
Erasca, Inc. is a biotech company focused on developing oncology drugs to combat cancers caused by mutations in the RAS signaling pathway. This chart shows the state of the economy, but for ERAS, scientific progress is key. The company is targeting one of the most challenging targets in oncology, and its success could change the treatment paradigm for many types of cancer.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Erasca Inc.
Erasca, Inc. is a biotechnology company focused on developing cancer drugs targeting key oncogenic pathways. Its future depends entirely on success in clinical trials. This graph reflects the market's confidence in the scientific potential and future commercial success of its developments.
%20sales%20of%20the%20company%20Erasca%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Erasca-Inc.&v=1772568393985 "Schedule of future (projected) sales of the company Erasca Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Erasca, Inc. is a biotech company whose mission is to erase cancer. It develops targeted therapies that target key drivers of oncological diseases. The chart shows forecasts for the cancer treatment sector. Erasca is betting that its scientific approaches will lead to the creation of breakthrough drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772568393990 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Erasca, Inc. is a biotechnology company focused on developing drugs for cancer caused by mutations in the RAS signaling pathway. Its market capitalization is dependent on the success of clinical trials. This curve, reflecting overall economic confidence, influences investor willingness to invest in long-term, high-risk scientific projects, which is critical for Erasca.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772568394089 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Erasca Inc.
Erasca, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. While in clinical trials, it incurs significant R&D expenditures. This chart illustrates the company's significant investments in research in the hopes of creating effective and profitable drugs.
Market segment marginality - Cancer cure
Erasca, Inc. is a biotech company focused on developing oncology drugs targeting key cancer cell signaling pathways (RAS/MAPK). This chart shows the average profitability in the oncology sector. Its mission to "eradicate cancer" and the breakthrough potential of its developments could lead to very high profitability in the future.
Market marginality as a whole
Erasca, Inc. is a biotechnology company focused on developing oncology drugs that target key signaling pathways in cancer cells. It is currently in clinical trials. This total revenue chart highlights that Erasca's business is an investment in future cancer treatments, not a mere profit generator, as is the case with most companies.
Employees in the company, segment and market as a whole
Number of employees in the company Erasca Inc.
Erasca is a biotech company focused on key cancer pathways. Its team consists primarily of scientists and clinical development specialists. This chart shows the human capital the company is devoting to advancing its portfolio of targeted oncology drugs.
Share of the company's employees Erasca Inc. within the market segment - Cancer cure
Erasca, Inc. is a biotechnology company whose mission is to erase cancer. It is focused on developing targeted therapies against key oncogenic mutations. This chart shows the percentage of leading scientists in the field of targeted oncology that Erasca attracts. It reflects its scientific ambition and the concentration of talent working on this complex task.
Number of employees in the market segment - Cancer cure
Erasca, Inc. is a biotech company whose mission is to discover cures for cancer caused by mutations in the RAS/MAPK signaling pathway. The growth of its scientific and clinical teams, which can be seen in the graph, is an indicator of progress. This increase in staff indicates that several drug candidates are actively advancing through clinical trials.
Number of employees in the market as a whole
Erasca, Inc. is a biotechnology company focused on fighting cancer. Its activities are entirely focused on scientific research and clinical trials. This overall workload does not affect its prospects. Erasca's value lies in its potential to create breakthrough drugs that will save lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Erasca Inc. (ERAS)
Erasca, Inc. is a biotech company focused on oncology. Its market capitalization reflects investors' bet on the success of its scientific developments. This chart clearly demonstrates how the market values intellectual capital in biotech. The company's entire value is attributed to its small team of scientists.
%20of%20the%20company%20Erasca%20Inc.%20(ERAS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Erasca-Inc.-ERAS&v=1772568394404 "Chart of market capitalization per employee (in thousands of dollars) of the company Erasca Inc. (ERAS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Erasca, Inc. is a biotechnology company focused on developing targeted cancer therapies. Its market capitalization is based on research potential, not current operations. This chart illustrates how investors value the intellectual capital and clinical program prospects per research team member.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772568394555 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Erasca, Inc. is a clinical-stage biotechnology company focused on developing drugs to combat cancer caused by mutations in the RAS signaling pathway. The chart shows the company's advanced science valuation. The very high market capitalization per employee reflects the complexity of the project and the enormous potential for success.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772568394814 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Erasca Inc. (ERAS)
Erasca, Inc. is a biotech company focused on cancer treatment. They are in the early stages of R&D. Like most biotechs at this stage, this graph likely shows a negative value. It measures the investment (loss) per scientist. This is the cost of funding high-risk research into new cancer treatments.
%20Chart%20Erasca%20Inc.%20(ERAS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Erasca-Inc.-ERAS&v=1772568394907 "Company Profit Per Employee (in thousands of dollars) Chart Erasca Inc. (ERAS)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Erasca (ERAS) is a biotech R&D company (oncology, RAS inhibitors). This chart shows the benchmark for "Cancer Treatment" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772568394955 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Erasca (ERAS) is a clinical-stage biotech focused on oncology, specifically on RAS/MAPK signaling pathway inhibitors. The company is in the R&D phase and is not profitable. This chart shows the investment (loss) per scientist working on developing next-generation cancer drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772568395077 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Erasca Inc. (ERAS)
Erasca, Inc. is a biotech company focused on developing cancer drugs. For a clinical-stage company, this graph reflects the monetization of its scientific platform through strategic partnerships. Increased revenue per employee is typically driven by upfront payments from large pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Erasca-Inc.-ERAS&v=1772568395078 "Sales chart per company employee Erasca Inc. (ERAS)")
Sales per employee in the market segment - Cancer cure
Erasca (ERAS) is a clinical-stage biotech company focused on developing cancer drugs (targeted therapies). The company has no approved products or commercial revenue. This graph doesn't reflect their value. As with other R&D biotechs, staff productivity on this graph would be zero. The company is relying entirely on the success of clinical trials.
Sales per employee for the market as a whole
Erasca is a biotech company focused on oncology. At the clinical development stage, this figure is expectedly low. The company is investing in its research staff without a commercial product. This timeline is important for tracking the future transition to commercialization and assessing the potential operating leverage of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Erasca Inc. (ERAS)
Erasca (ERAS) is an oncology company focused on one of the most challenging targets in medicine—the RAS/MAPK signaling pathway, which drives many cancers. This chart shows bearish bets. Bears believe this target is untreatable, and their clinical trials are likely to fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Erasca-Inc.-ERAS&v=1772568395303 "Short Shares Chart for the Company Erasca Inc. (ERAS)")
Shares shorted by market segment - Cancer cure
Erasca (ERAS) is a clinical-stage biotech focused on developing cancer drugs targeting previously invulnerable targets (RAS/MAPK pathway). This chart is a barometer of sentiment across the biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Erasca, this signals a "venture drought."
Shares shorted by the overall market
Erasca is a clinical-stage biotech company searching for a cure for cancer. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require constant refinancing for R&D, and ERAS is caught in the middle of this sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Erasca Inc. (ERAS)
Erasca (ERAS) is a biotech company focused on developing drugs to treat cancer caused by mutations in the RAS/MAPK pathway. This is a speculative R&D bet. This chart is a momentum oscillator. It shows when expectations for early clinical data are pushing the stock into overheated territory (above 70) or when delays and high cash burn are leading to oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Erasca-Inc.-ERAS&v=1772568395523 "RSI 14 indicator chart for the company's stock Erasca Inc. (ERAS)")
RSI 14 Market Segment - Cancer cure
Erasca (ERAS) is a biotech focused on "erasing" cancer (hence the name). They develop targeted drugs that target key tumor growth drivers. This chart measures overall sentiment in the Oncology sector. It helps distinguish Erasca's trial success from overall "overheating" or "overselling" across the biotech sector.
RSI 14 for the overall market
For Erasca, an oncology biotech, this graph is a lifeline. Its survival depends on "cash for research." During periods of market euphoria, investors are willing to fund risky but promising developments. During periods of panic, the cash flow is turned off, and companies like Erasca can face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ERAS (Erasca Inc.)
Erasca (ERAS) is a clinical-stage biopharmaceutical company focused on cancer treatment. Its mission is to "erase" cancer by targeting key tumor survival pathways (e.g., RAS/MAPK). This chart shows the average 12-month Wall Street forecast. It reflects analysts' assessments of early clinical trial data and the potential of its development pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ERAS-Erasca-Inc.&v=1772568395628 "A chart showing analyst consensus forecasts for the expected stock price. ERAS (Erasca Inc.)")
The difference between the consensus estimate and the actual stock price ERAS (Erasca Inc.)
Erasca is a biotech focused on one of the most challenging targets in oncology: developing drugs against mutations in the KRAS genes and the RAS/MAPK pathway. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, demonstrating whether experts believe in their scientific approach to this untreatable target.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ERAS-Erasca-Inc.&v=1772568395655 "A chart showing the difference between the consensus forecast and the actual stock price. ERAS (Erasca Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Erasca is a biotech company whose mission is to "erase" cancer. It focuses on developing drugs that target key oncogenes (such as RAS/MAPK). This chart shows overall expectations for the cancer treatment sector. It reflects whether experts believe a breakthrough can be achieved in treating the most challenging tumors.
Analysts' consensus forecast for the overall market share price
Erasca (ERAS) is a cutting-edge biotech developing targeted therapies for cancer. It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Erasca Inc.
Erasca is a biotech company with a mission. Their goal is to erase cancer. They focus on nodes in cancer signaling pathways (the RAS/MAPK family), which are the main drivers of tumors. This graph is an assessment of their R&D pipeline. It reflects the market's faith in their scientific approach and expectations for clinical data on their targeted drug portfolio.
AKIMA Market Segment Index - Cancer cure
Erasca (ERAS) is a clinical-stage biotech focused on oncology; the company is developing a portfolio of innovative drugs targeting key cancer drivers (the RAS/MAPK pathway). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus (ERAS) on cancer differentiate it from the average pharma company?
The AKIM Index for the overall market
Erasca is a precision oncology company targeting the RAS/MAPK pathways that cause cancer. They are mutation hunters. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this ambitious scientific story stacks up against the backdrop of broader economic trends affecting biotech.
